线粒体与外泌体miR137-COX6A2及gamma同步化作为精神分裂症中间神经元与临床指标生物标志物
该研究在氧化还原失调小鼠模型中发现氧化应激诱导miR-137上调、COX6A2与线粒体自噬标志物下降及受损线粒体累积,MitoQ可逆转这些过程。转化至早期精神病患者,血外泌体miR-137升高、COX6A2降低且线粒体自噬标志物改变,并与EEG ASSR gamma振荡减弱相关,提示其反映PV中间神经元微环路损伤。患者可分线粒体功能障碍型(Psy-D)与无/低障碍型(Psy-ND),Psy-D者ASSR损害更重且精神病理、神经认知及功能更差。
要点
- 血外泌体miR-137升高与COX6A2降低可能作为PV中间神经元微环路损伤的外周替代标志物。
- 早期精神病患者可按线粒体功能障碍分层为Psy-D与Psy-ND,Psy-D临床与认知功能更差。
- 该分层有望高选择性和特异性筛选针对脑线粒体失调治疗的患者并评估疗效。
核心结论
- 血外泌体miR-137/COX6A2水平改变可能反映精神分裂症PV中间神经元线粒体损伤,并可将早期精神病患者分层为Psy-D与Psy-ND。
研究设计与样本
- 研究采用氧化还原失调小鼠模型(Gclm-KO ± GBR)并结合早期精神病患者(EPP)血液外泌体与EEG ASSR检测进行转化验证。
主要发现
- 在Gclm-KO ± GBR小鼠前额叶与血液中,氧化应激诱导miR-137上调,导致COX6A2及线粒体自噬标志物(NIX、Fundc1、LC3B)下降和受损线粒体累积,加重氧化应激与PV中间神经元损伤。
- MitoQ可 rescue 上述所有过程。
- EPP患者血外泌体miR-137升高、COX6A2降低并伴线粒体自噬标志物改变,提示动物模型的中枢与外周观察反映于患者血液。
- 较高的外泌体miR-137和较低的COX6A2水平与EEG中ASSR gamma振荡减弱相关。
- EPP可分为线粒体功能障碍组(Psy-D,外泌体高miR-137、低COX6A2)与无/低线粒体损伤组(Psy-ND,miR-137与COX6A2在对照范围);Psy-D患者ASSR反应更受损,精神病理、神经认知及整体与社会功能更差。
关键数值与推荐
- Psy-D亚组定义为外泌体高miR-137与低COX6A2水平;Psy-ND亚组miR-137与COX6A2水平在对照范围内。
- 该分层据称具有高选择性和特异性,可用于筛选针对脑线粒体失调治疗的患者并捕捉未来临床试验的临床与功能疗效。
临床怎么用
- 对早期精神病患者可检测血外泌体miR-137与COX6A2水平,辅助识别线粒体功能障碍亚型(Psy-D)并评估疾病严重度。
- 结合EEG ASSR gamma振荡评估PV中间神经元相关网络功能,可能有助于监测疾病进展与治疗反应。
- 针对脑线粒体失调的抗氧化治疗(如MitoQ类)可能优先用于Psy-D亚组,但需未来临床试验验证。
局限性
- 研究结果基于动物模型与早期精神病患者样本,需进一步独立队列验证外泌体标志物的诊断与分层效能。
- MitoQ的 rescue 效应仅来自动物模型,尚未在患者中证实临床疗效。
- 原文未报告样本量、具体数值、置信区间与P值等统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early detection and intervention in schizophrenia requires mechanism-based biomarkers that capture neural circuitry dysfunction, allowing better patient stratification, monitoring of disease progression and treatment. In prefrontal cortex and blood of redox dysregulated mice (Gclm-KO ± GBR), oxidative stress induces miR-137 upregulation, leading to decreased COX6A2 and mitophagy markers (NIX, Fundc1, and LC3B) and to accumulation of damaged mitochondria, further exacerbating oxidative stress and parvalbumin interneurons (PVI) impairment. MitoQ, a mitochondria-targeted antioxidant, rescued all these processes. Translating to early psychosis patients (EPP), blood exosomal miR-137 increases and COX6A2 decreases, combined with mitophagy markers alterations, suggest that observations made centrally and peripherally in animal model were reflected in patients' blood. Higher exosomal miR-137 and lower COX6A2 levels were associated with a reduction of ASSR gamma oscillations in EEG. As ASSR requires proper PVI-related networks, alterations in miR-137/COX6A2 plasma exosome levels may represent a proxy marker of PVI cortical microcircuit impairment. EPP can be stratified in two subgroups: (a) a patients' group with mitochondrial dysfunction "Psy-D", having high miR-137 and low COX6A2 levels in exosomes, and (b) a "Psy-ND" subgroup with no/low mitochondrial impairment, including patients having miR-137 and COX6A2 levels in the range of controls. Psy-D patients exhibited more impaired ASSR responses in association with worse psychopathological status, neurocognitive performance, and global and social functioning, suggesting that impairment of PVI mitochondria leads to more severe disease profiles. This stratification would allow, with high selectivity and specificity, the selection of patients for treatments targeting brain mitochondria dysregulation and capture the clinical and functional efficacy of future clinical trials.
引用
- Khadimallah I, Jenni R, Cabungcal JH, et al. Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. Mol Psychiatry. 2021. PMID: 34686767. doi:10.1038/s41380-021-01313-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。